| Talimogene laherparepvec improves durable response rate in patients with advanced melanoma RH Andtbacka, HL Kaufman, F Collichio, T Amatruda, N Senzer, ... J clin Oncol 33 (25), 2780-2788, 2015 | 2674 | 2015 |
| Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy A Ribas, R Dummer, I Puzanov, A VanderWalde, RHI Andtbacka, ... Cell 170 (6), 1109-1119. e10, 2017 | 1292 | 2017 |
| Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study F Meric-Bernstam, H Hurwitz, KPS Raghav, RR McWilliams, M Fakih, ... The Lancet Oncology 20 (4), 518-530, 2019 | 519 | 2019 |
| Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients A Vanderwalde, D Spetzler, N Xiao, Z Gatalica, J Marshall Cancer medicine 7 (3), 746-756, 2018 | 435 | 2018 |
| Detection of NRG1 gene fusions in solid tumors S Jonna, RA Feldman, J Swensen, Z Gatalica, WM Korn, H Borghaei, ... Clinical Cancer Research 25 (16), 4966-4972, 2019 | 192 | 2019 |
| Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised … J Giralt, J Trigo, S Nuyts, M Ozsahin, K Skladowski, G Hatoum, JF Daisne, ... The lancet oncology 16 (2), 221-232, 2015 | 183 | 2015 |
| Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled … R Mesía, M Henke, A Fortin, H Minn, ACY Ancona, A Cmelak, ... The Lancet Oncology 16 (2), 208-220, 2015 | 179 | 2015 |
| OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx … RHI Andtbacka, FA Collichio, T Amatruda, NN Senzer, J Chesney, ... Journal of Clinical Oncology 31 (18_suppl), LBA9008-LBA9008, 2013 | 171 | 2013 |
| Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (vol 170, 1109. e1, 2017) A Ribas, R Dummer, I Puzanov, A VanderWalde, RHI Andtbacka, ... Cell 174 (4), 1031-1032, 2018 | 149 | 2018 |
| Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy A Ribas, R Dummer, I Puzanov, A VanderWalde, RHI Andtbacka, ... Cell 174 (4), 1031-1032, 2018 | 149 | 2018 |
| Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. GV Long, R Dummer, A Ribas, I Puzanov, A VanderWalde, ... Journal of Clinical Oncology 34 (15_suppl), 9568-9568, 2016 | 126 | 2016 |
| Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected … I Puzanov, MM Milhem, RHI Andtbacka, DR Minor, O Hamid, A Li, ... Journal of Clinical Oncology 32 (15_suppl), 9029-9029, 2014 | 98 | 2014 |
| Aging and osteoporosis in breast and prostate cancer A VanderWalde, A Hurria CA: a cancer journal for clinicians 61 (3), 139-156, 2011 | 88 | 2011 |
| Prevalence of class I–III BRAF mutations among 114,662 cancer patients in a large genomic database J Owsley, MK Stein, J Porter, GK In, M Salem, S O’Day, A Elliott, ... Experimental Biology and Medicine, 1535370220959657, 2020 | 60 | 2020 |
| Racial disparities in the molecular landscape of cancer EI Heath, F Lynce, J Xiu, A Ellerbrock, SK Reddy, E Obeid, SV Liu, ... Anticancer research 38 (4), 2235-2240, 2018 | 59 | 2018 |
| Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers K Mody, J Starr, M Saul, K Poorman, BA Weinberg, ME Salem, ... Journal of gastrointestinal oncology 10 (6), 1099, 2019 | 56 | 2019 |
| Second malignancies among elderly survivors of cancer AM VanderWalde, A Hurria The oncologist 16 (11), 1572, 2011 | 50 | 2011 |
| Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies AM VanderWalde, CL Sun, L Laddaran, L Francisco, S Armenian, ... Leukemia 27 (5), 1139-1145, 2013 | 48 | 2013 |
| Paying human subjects in research: where are we, how did we get here, and now what? A VanderWalde, S Kurzban The Journal of Law, Medicine & Ethics 39 (3), 543-558, 2011 | 47 | 2011 |
| Pertuzumab+ trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. H Hurwitz, KPS Raghav, HA Burris, R Kurzrock, C Sweeney, ... Journal of Clinical Oncology 35 (4_suppl), 676-676, 2017 | 46 | 2017 |
Anthony OlszanskiFox Chase Cancer Center在 fccc.edu 的电子邮件经过验证
